Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125041103/en/

Winnie partners with
Vitiligo is a chronic autoimmune condition characterized by loss of pigment in the skin, resulting in white patches that can appear anywhere on the body. Affecting an estimated 1.9 to 2.8 million adults in
Winnie has lived with vitiligo for most of her life and faced related challenges, including hurtful comments and lack of understanding from others about the condition. As part of the partnership, Winnie steps into her past in two new videos, revisiting her childhood and sharing advice for her younger self and others on similar journeys.
“Growing up with vitiligo, I often felt like I was the only person in the world like me,” said
In the videos, Winnie reflects on how misconceptions about vitiligo have shaped her experiences and identity. She also emphasizes the importance of people learning about the condition and engaging with healthcare professionals and choosing for themselves how they manage vitiligo. By connecting Winnie’s past with her present, the campaign validates every experience and encourages people to choose their own paths.
“People living with vitiligo are the experts of their own experiences. As a dermatologist, I recognize how important it is to listen to them and partner closely on a personalized approach built on their goals and choices,” said
“Each person's journey with vitiligo is unique. We are honored to partner with Winnie to share and amplify her personal story as part of our commitment to highlighting the lived experiences of people with vitiligo,” said
To learn more about vitiligo and Winnie’s journey, visit ThisIsVitiligo.com.
About
About Incyte Dermatology
Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.
We strive to identify and develop therapies to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis. Specifically, our efforts in dermatology are focused on a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, hidradenitis suppurativa and prurigo nodularis.
To learn more, visit the Dermatology section of Incyte.com.
About
A global biopharmaceutical company on a mission to Solve On.,
For additional information on
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the partnership between
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and other regulatory agencies; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended
____________________________
1 Results were from a cross-sectional, population-based, participant self-reported and clinician adjudicated online survey conducted between
2 Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of vitiligo among adults in
3 Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159-164.
4 Bibeau K,
View source version on businesswire.com: https://www.businesswire.com/news/home/20251125041103/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: